Our findings showed that FXR-induced IL-6/IL-6ST/Jak2/STAT3 signaling promoted NSCLC metastasis, highlighting a novel therapeutic option for treating advanced or metastatic NSCLC. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.